News | May 02, 2026
Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr
The company posted revenue of Rs. 703 crore in Q4 FY26
The company posted revenue of Rs. 703 crore in Q4 FY26
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Targets high-growth eye care expansion push
Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership
Capital infusion to accelerate Earendil’s R&D platform
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Subscribe To Our Newsletter & Stay Updated
